Navigation Links
Vaccine for metastatic breast, ovarian cancer shows promise
Date:11/8/2011

PHILADELPHIA Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients," said lead researcher James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.

Gulley and colleagues enrolled 26 patients and assigned them to monthly vaccinations with the PANVAC vaccine, which contains transgenes for MUC-1, CEA and three T cell costimulatory molecules.

These patients were already heavily pretreated, with 21 of them receiving at least three prior chemotherapy regimens.

Among the 12 patients with breast cancer, median time to progression was 2.5 months and median overall survival was 13.7 months. Four patients had stable disease.

For the 14 patients with ovarian cancer, median time to progression was two months and median overall survival was 15 months.

Following treatment, mild injection-site reactions were the most common side effect.

According to Gulley, interest in cancer vaccines is increasing and more study is needed to determine which vaccines will benefit which patients. "The sustained benefit seen in some patients in this study underscores the potential for therapeutic vaccines to impact clinical outcomes without toxicity," he said. "However, more studies in the appropriate patient populations are required to adequately assess efficacy."

The study was funded by the National Cancer Institute.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Vitamin D, Interferon Alpha Vaccine Show Promise Against Lupus
2. NIH scientists outline steps toward Epstein-Barr virus vaccine
3. Multiple malaria vaccine offers protection to people most at risk
4. HPV Vaccine Might Help Prevent Anal Cancers: Study
5. Researchers develop method to better estimate vaccine coverage
6. Flu Vaccine Isnt Foolproof
7. U.S. Health Officials Back HPV Vaccine for Boys
8. IADR/AADR publish study on dental caries vaccine
9. Study: Obesity limits effectiveness of flu vaccines
10. Experimental Vaccine Shows Promise for Lung Cancer: Study
11. Next-generation allergy vaccines to be developed in Finland to create effective and safe desensitization therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter has openings ... to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 ... Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the Metroplex. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... as one of Canada’s top Information and Communication Technology (ICT) companies in the ... and Multinational ICT companies operating in Canada, as ranked by revenue. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... the latest release of DocAve 6 Service Pack (SP) 7, the ... to SharePoint 2016 and take advantage of the platform’s latest features – whether ...
(Date:5/3/2016)... ... 2016 , ... Hydra Skin Sciences, a top-rated skincare company based ... new anti-aging skin care product that integrates Snow Algae Powder and six ... seventy-five thousand units worldwide within the first two months of release. , “We set ...
(Date:5/3/2016)... ... May 03, 2016 , ... On ... the line’s largest cruise ship ever. To help guests explore this new ... the Carnival Vista ’s most exciting features and accommodations. , Explore ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor ... story and encourage those at risk to get tested and begin the road to a ... ... ... Pharmacy, Inc.) ...
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... 2016 Intec Pharma Ltd. (NASDAQ: ... company, today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in ... outstanding track record, having supported the advancement of several ... in the United States and ...
Breaking Medicine Technology: